Quick Answer
Co-Diagnostics, Inc. reported Net Income Loss of -$46.90 million for the year ending 2025.
- Co-Diagnostics, Inc. showed a decrease of -24.6% in Net Income Loss from 2024 to 2025.
- This data is from Co-Diagnostics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2016: -$442.6 thousand | Q3 2016: -$450.0 thousand | Q1 2017: -$705.7 thousand | Q2 2017: -$855.0 thousand | Q3 2017: -$3.89 million | Q1 2018: -$1.31 million | Q2 2018: -$1.37 million | Q3 2018: -$1.64 million | Q1 2019: -$1.37 million | Q2 2019: -$1.34 million | Q3 2019: -$1.75 million | Q1 2020: -$1.07 million | Q2 2020: $15.01 million | Q3 2020: $15.73 million | Q1 2021: $7.90 million | Q2 2021: $9.79 million | Q3 2021: $11.48 million | Q1 2022: $11.71 million | Q2 2022: -$2.69 million | Q3 2022: -$1.36 million | Q1 2023: -$5.76 million | Q2 2023: -$8.92 million | Q3 2023: -$5.98 million | Q1 2024: -$9.31 million | Q2 2024: -$7.60 million | Q3 2024: -$9.70 million | Q1 2025: -$7.53 million | Q2 2025: -$7.73 million | Q3 2025: -$5.89 million.
- Over the full 10 years of available data (2016 to 2025), Co-Diagnostics, Inc.'s Net Income Loss has declined by 2,331.5%.
- Historical annual values: Fiscal year 2025: -$46.90 million | Fiscal year 2024: -$37.64 million | Fiscal year 2023: -$35.33 million | Fiscal year 2022: -$14.24 million | Fiscal year 2021: $36.66 million | Fiscal year 2020: $42.48 million | Fiscal year 2019: -$6.20 million | Fiscal year 2018: -$6.27 million | Fiscal year 2017: -$6.96 million | Fiscal year 2016: -$1.93 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: